Bicocca Open Archive

Logo unimib boa
CAZZANIGA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.643
AS - Asia 13.000
EU - Europa 11.174
SA - Sud America 2.079
AF - Africa 224
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 22
Totale 52.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.104
SG - Singapore 4.790
CN - Cina 3.049
IT - Italia 2.278
HK - Hong Kong 2.273
RU - Federazione Russa 2.021
BR - Brasile 1.647
VN - Vietnam 1.576
IE - Irlanda 1.385
SE - Svezia 1.365
DE - Germania 1.317
UA - Ucraina 752
GB - Regno Unito 572
CA - Canada 389
FI - Finlandia 293
FR - Francia 250
IN - India 248
AT - Austria 245
ID - Indonesia 196
KR - Corea 182
AR - Argentina 176
NL - Olanda 155
TR - Turchia 143
ES - Italia 123
BD - Bangladesh 113
MX - Messico 103
PL - Polonia 99
ZA - Sudafrica 97
JP - Giappone 95
DK - Danimarca 76
EC - Ecuador 71
BE - Belgio 66
IQ - Iraq 65
PK - Pakistan 47
CO - Colombia 42
VE - Venezuela 38
SA - Arabia Saudita 33
PY - Paraguay 32
CH - Svizzera 27
UZ - Uzbekistan 25
EG - Egitto 24
PE - Perù 24
CL - Cile 23
AE - Emirati Arabi Uniti 20
CZ - Repubblica Ceca 20
AU - Australia 19
GR - Grecia 19
BG - Bulgaria 18
LT - Lituania 18
MA - Marocco 18
KE - Kenya 17
PT - Portogallo 17
TN - Tunisia 17
EU - Europa 16
IR - Iran 16
IL - Israele 15
RO - Romania 13
UY - Uruguay 13
AZ - Azerbaigian 12
KZ - Kazakistan 12
ET - Etiopia 11
JO - Giordania 11
LB - Libano 11
NO - Norvegia 11
PA - Panama 10
DZ - Algeria 9
TW - Taiwan 9
DO - Repubblica Dominicana 7
JM - Giamaica 7
KG - Kirghizistan 7
BO - Bolivia 6
MU - Mauritius 6
NP - Nepal 6
NZ - Nuova Zelanda 6
OM - Oman 6
PH - Filippine 6
TH - Thailandia 6
HU - Ungheria 5
MY - Malesia 5
TT - Trinidad e Tobago 5
AL - Albania 4
CR - Costa Rica 4
EE - Estonia 4
LK - Sri Lanka 4
NI - Nicaragua 4
RE - Reunion 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SR - Suriname 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
GA - Gabon 3
GY - Guiana 3
HN - Honduras 3
KW - Kuwait 3
LV - Lettonia 3
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
Totale 52.125
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.634
Singapore 2.774
Fairfield 2.293
Hong Kong 2.257
Ashburn 2.173
Woodbridge 2.114
Houston 1.677
Dublin 1.352
Chandler 1.252
Wilmington 1.068
Seattle 889
Cambridge 799
Frankfurt am Main 792
Jacksonville 759
Milan 677
New York 666
Dearborn 605
Santa Clara 546
Princeton 492
Ho Chi Minh City 488
Beijing 487
Los Angeles 387
Hefei 373
Hanoi 331
Dallas 321
Lawrence 239
Nanjing 232
Altamura 224
Moscow 212
Shanghai 210
Chicago 198
Vienna 186
The Dalles 183
Seoul 173
São Paulo 167
Buffalo 164
Jakarta 157
San Diego 150
Lachine 124
Munich 110
Toronto 104
Guangzhou 94
Nuremberg 84
Helsinki 83
Warsaw 83
London 81
Dong Ket 80
Andover 79
Nanchang 79
Council Bluffs 77
Lissone 76
Rome 73
Denver 72
Brooklyn 69
Montreal 67
Shenyang 67
Tianjin 63
Tokyo 63
Changsha 62
Fuzhou 61
Brussels 59
Boardman 57
Salt Lake City 57
Hebei 55
Jinan 53
Orem 53
Rio de Janeiro 53
Phoenix 49
Poplar 49
Stockholm 49
Haiphong 47
Johannesburg 44
Turku 43
Chennai 42
Norwalk 41
Da Nang 39
Zhengzhou 38
Lappeenranta 36
Boston 35
Paris 35
Biên Hòa 34
Falls Church 34
Ha Long 34
Hangzhou 34
Belo Horizonte 33
Jiaxing 33
Amsterdam 31
Pune 31
San Francisco 31
Atlanta 30
Curitiba 30
Fremont 30
Ningbo 30
Quận Bình Thạnh 30
San Jose 30
Turin 30
Hải Dương 29
Kent 29
Kunming 29
Monza 29
Totale 35.007
Salva come PNG Salva come JPEG
Nome #
Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development 457
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica] 455
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 452
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche 410
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 395
NIPBL: a new player in myeloid cells differentiation 388
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 386
IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia 376
Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group 375
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 372
Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation 369
A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia 355
Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome 353
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 351
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 340
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection 326
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 321
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia 319
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 317
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 309
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 309
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 307
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 306
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation 299
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 298
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 294
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression 283
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations 283
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 282
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model 280
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 278
Idiopathic erythrocytosis: a germline disease? 275
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting 275
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement 275
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection 273
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 270
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome 269
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia 264
The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia 260
Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform 254
PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells 254
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 254
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 254
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia 253
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia 251
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 250
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 250
Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts 248
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia 248
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 248
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 244
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype 243
Characterization of children with FLT3-ITD acute myeloid leukemia: A report from the AIEOP AML-2002 study group 238
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 238
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 238
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 237
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 235
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 234
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation 234
PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 233
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 233
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia 232
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response 231
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 229
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia 229
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 227
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 227
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 227
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 227
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". 225
What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? 225
The KMT2A recombinome of acute leukemias in 2023 224
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 224
Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome 223
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study 223
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 223
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 223
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: Another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma 221
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia 220
Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions 219
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 218
Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia 218
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL 217
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 217
Metabolic gatekeeper function of B-lymphoid transcription factors 217
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias 216
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome 216
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 216
CyclinD1 Down-Regulation and Increased Apoptosis Are Common Features of Cohesinopathies 215
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 214
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells 213
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial 211
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis 210
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency 209
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia 208
γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia 208
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study 207
Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis 207
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 202
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 202
Totale 26.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.594
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 183.594
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.576 0 0 0 0 0 436 816 678 399 494 350 403
2021/20223.278 232 342 419 237 256 271 123 177 208 230 227 556
2022/20235.119 663 1.625 374 426 282 793 67 292 332 31 154 80
2023/20244.081 119 130 173 185 528 1.087 816 152 357 85 81 368
2024/20259.831 466 1.067 552 447 866 311 662 292 1.069 1.516 861 1.722
2025/202613.043 3.009 1.663 1.751 2.696 2.926 998 0 0 0 0 0 0
Totale 53.376